Zinger Key Points
- Capri Holdings Q3 adjusted earnings miss estimates, with revenue down 11.6% year-over-year.
- FY25 and FY26 revenue outlook signal challenges for Versace and other brands.
Capri Holdings Limited CPRI shares are trading lower in the premarket session on Wednesday.
The company reported that third-quarter adjusted earnings per share was 45 cents, missing the street view of 66 cents. Quarterly sales of $1.26 billion aligned with the analyst consensus estimate.
Revenue decreased 11.6% on a reported basis and 11.4% in constant currency. Total company retail sales declined low-double-digits while wholesale revenue decreased low-teens.
Versace revenue of $193 million decreased 15% on both a reported and constant currency basis compared to prior year. Jimmy Choo revenue of $159 million decreased 4.2% on both a reported and constant currency basis compared to prior year. Michael Kors revenue of $909 million decreased 12.1% on a reported basis and 11.7% on a constant currency basis.
Gross profit was $812 million and gross margin was 64.4%. Gross profit margin declined 60 basis points primarily due to lower full price sell-throughs.
Net inventory as of December 28, 2024, was $892 million, a 13% decrease compared to the prior year.
Cash and equivalents totaled $356 million, and total borrowings outstanding were $1.48 billion, resulting in a net debt of $1.12 billion as of December 28, versus $1.60 billion last year.
Outlook: Capri Holdings expects FY25 revenue of $4.40 billion, below the $4.51 billion estimate. Versace’s revenue is expected to be around $810 million, impacted by $10 million in foreign currency losses.
For FY26, Capri projects $4.10 billion in revenue, lower than the $4.52 billion estimate, with Versace’s revenue expected at $800 million, impacted by $25 million in foreign currency losses.
Price Action: CPRI shares are trading lower by 5.12% to $22.80 premarket at last check Wednesday.
Read Next:
Photo: Giorgio Borelli/Shutterstock.com.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.